Pharmaceutical compound
| Combination of | |
|---|---|
| Memantine | NMDA receptor antagonist |
| Donepezil | Acetylcholinesterase inhibitor |
| Clinical data | |
| Trade names | Namzaric |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Memantine/donepezil, sold under the brand name Namzaric among others, is a fixed dose combination medication used for the treatment of dementia of the Alzheimer's type. It contains memantine, as the hydrochloride, a NMDA receptor antagonist; and donepezil as the hydrochloride, an acetylcholinesterase inhibitor. It is taken by mouth.
Memantine/donepezil was approved for medical use in the United States in 2014.
References
- ^ "Namzaric- memantine hydrochloride and donepezil hydrochloride capsule; Namzaric- memantine hydrochloride and donepezil hydrochloride kit". DailyMed. 22 January 2019. Archived from the original on 20 January 2022. Retrieved 22 December 2023.
- "Periodic safety update report single assessment donepezil / memantine". European Medicines Agency. 7 March 2024. Retrieved 2 May 2024.
- "Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules". U.S. Food and Drug Administration (FDA). 13 May 2015. Archived from the original on 22 December 2023. Retrieved 22 December 2023.
Further reading
- Calhoun A, King C, Khoury R, Grossberg GT (October 2018). "An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease". Expert Opinion on Pharmacotherapy. 19 (15): 1711–1717. doi:10.1080/14656566.2018.1519022. PMID 30244611. S2CID 52336224.
| Psychoanaleptics: Anti-dementia agents (ATC code N06D and others) | |
|---|---|
| AChE inhibitor medications | |
| Other medications | |
| Experimental BACE inhibitors | |
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |